BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

...in glioblastoma and EGFR-positive solid tumors that metastasize to the brain. NewGen Therapeutics Inc. and Kanion Pharmaceutical Co. Ltd....
BioCentury | Apr 29, 2013
Clinical News

NewGen, Kanion preclinical data

...NT-113 from Kanion (see BioCentury, Jan. 2, 2012). NewGen Therapeutics Inc. , Menlo Park, Calif. Kanion Pharmaceutical Co. Ltd....
BioCentury | Jan 16, 2012
Emerging Company Profile

NewGen: Compositions matter

...of three cancer programs from the Kanion USA Inc. drug discovery subsidiary of Chinese biopharma Kanion Pharmaceutical Co. Ltd....
...one of the remaining programs into Phase I and potentially Phase II testing. Wang Shen, Kanion...
...co-founder and VP of R&D of NewGen. Shen, a medicinal chemist, works full time for Kanion...
BioCentury | Jan 2, 2012
Company News

NewGen, Kanion deal

...NewGen acquired exclusive, ex-Chinese rights from Kanion's Kanion USA Inc. U.S. subsidiary to develop and commercialize...
...Kanion USA Inc. U.S. subsidiary to develop and commercialize three preclinical cancer programs. In exchange, Kanion...
...Menlo Park, Calif. Kanion Pharmaceutical Co. Ltd. (Shanghai:600557), Lianyungang, China NewGen acquired exclusive, ex-Chinese rights from Kanion's Kanion...
Items per page:
1 - 4 of 4
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

...in glioblastoma and EGFR-positive solid tumors that metastasize to the brain. NewGen Therapeutics Inc. and Kanion Pharmaceutical Co. Ltd....
BioCentury | Apr 29, 2013
Clinical News

NewGen, Kanion preclinical data

...NT-113 from Kanion (see BioCentury, Jan. 2, 2012). NewGen Therapeutics Inc. , Menlo Park, Calif. Kanion Pharmaceutical Co. Ltd....
BioCentury | Jan 16, 2012
Emerging Company Profile

NewGen: Compositions matter

...of three cancer programs from the Kanion USA Inc. drug discovery subsidiary of Chinese biopharma Kanion Pharmaceutical Co. Ltd....
...one of the remaining programs into Phase I and potentially Phase II testing. Wang Shen, Kanion...
...co-founder and VP of R&D of NewGen. Shen, a medicinal chemist, works full time for Kanion...
BioCentury | Jan 2, 2012
Company News

NewGen, Kanion deal

...NewGen acquired exclusive, ex-Chinese rights from Kanion's Kanion USA Inc. U.S. subsidiary to develop and commercialize...
...Kanion USA Inc. U.S. subsidiary to develop and commercialize three preclinical cancer programs. In exchange, Kanion...
...Menlo Park, Calif. Kanion Pharmaceutical Co. Ltd. (Shanghai:600557), Lianyungang, China NewGen acquired exclusive, ex-Chinese rights from Kanion's Kanion...
Items per page:
1 - 4 of 4